Stefania Pittaluga

机构：National Institutes of Health, National Cancer Institute, National Cancer Institute, Center for Cancer Research, New York University · ORCID：0000-0001-7688-1439

发表论文 803 篇 · 总被引 46807 次 · h-index 116

代表论文

• Performance of expanded diagnostic criteria for APECED in independent cohorts and implications for earlier diagnosis (2026 · JCI Insight · 被引 1)
• Clinical Spectrum and Therapeutic Options in Monogenic CTLA-4-, LRBA-, or SOCS1-Related Primary Immune Regulatory Disorders (2026 · The Journal of Allergy and Clinical Immunology In Practice · 被引 1)
• DNA methylation-based classification of hematolymphoid neoplasms (2026 · Blood Advances · 被引 1)
• Ruxolitinib prevents irreversible autoimmune endocrinopathies in APECED (2026 · Nature Communications)
• Abstract A047: Final analysis of a Phase 1 study of ibrutinib dose-escalation in TEDDI-R with isavuconazole for relapsed or refractory primary DLBCL of the CNS (2026 · Blood Cancer Discovery)
• Abstract A027: Combination targeted therapy with ViPOR in relapsed/refractory (R/R) and treatment-naïve (TN) mantle cell lymphoma (MCL): Analysis of safety, efficacy, and minimal residual disease (MRD) (2026 · Blood Cancer Discovery)